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ABSTRACT: Cyclic adenosine 5′-diphosphate ribose
(cADPR) analogs based on the cyclic inosine 5′-diphosphate
ribose (cIDPR) template were synthesized by recently
developed stereo- and regioselective N1-ribosylation. Replac-
ing the base N9-ribose with a butyl chain generates inhibitors
of cADPR hydrolysis by the human ADP-ribosyl cyclase CD38
catalytic domain (shCD38), illustrating the nonessential nature
of the “southern” ribose for binding. Butyl substitution
generally improves potency relative to the parent cIDPRs, and 8-amino-N9-butyl-cIDPR is comparable to the best noncovalent
CD38 inhibitors to date (IC50 = 3.3 μM). Crystallographic analysis of the shCD38:8-amino-N9-butyl-cIDPR complex to a 2.05 Å
resolution unexpectedly reveals an N1-hydrolyzed ligand in the active site, suggesting that it is the N6-imino form of cADPR that
is hydrolyzed by CD38. While HPLC studies conﬁrm ligand cleavage at very high protein concentrations, they indicate that
hydrolysis does not occur under physiological concentrations. Taken together, these analogs conﬁrm that the “northern” ribose is
critical for CD38 activity and inhibition, provide new insight into the mechanism of cADPR hydrolysis by CD38, and may aid
future inhibitor design.
■ INTRODUCTION
Cyclic adenosine 5′-diphosphate ribose (cADPR, 1, Figure 1)1,2
is synthesized in biological systems from nicotinamide adenine
dinucleotide (NAD+) by ADP-ribosyl cyclases (ADPRCs). It
acts as a second messenger, mobilizing intracellular calcium.3−6
In humans, formation of cADPR is catalyzed by the
multifunctional transmembrane glycoprotein ADPRC CD38.7
CD38 also acts as an NAD+ glycohydrolase (NADase) and as a
cADPR hydrolase to generate adenosine 5′-diphosphate ribose
(ADPR), another Ca2+-releasing second messenger.8−10 Under
acidic conditions, CD38 generates the most potent Ca2+-
releasing second messenger known to date, nicotinic acid
adenine dinucleotide phosphate (NAADP) from nicotinamide
adenine dinucleotide phosphate (NADP).11
CD38 knockout studies have revealed the importance of this
pathway in a range of diseases. CD38 is a marker in AIDS
progression12 and a negative prognostic marker of chronic
lymphocytic leukemia.13 It acts to regulate intracellular levels of
NAD+, being implicated in energy homeostasis, signal trans-
duction, and aging,14−16 and recently has been shown to be
critical for social behavior in mice.17 The emerging role of
CD38 in disease states is stimulating the search for modulators
of activity for chemical biological studies and to provide
structural clues for drug design and potential therapeutic
candidates.18 To date, CD38 inhibitors fall broadly into two
categories: mechanism-based covalent inhibitors that bind to
the catalytic residue, and reversible, competitive, noncovalent
inhibitors. Most are derived from NAD+ and designed as
inhibitors of the predominant NADase activity of CD38.
Nicotinamide-based derivatives have demonstrated nanomolar
inhibition of NADase activity by covalent modiﬁcation of
CD38 19 and low millimolar activity when designed as
membrane permeable analogs.20 Competitive inhibitors are
more diverse in structure, with a nonhydrolyzable NAD+ analog
reported (IC50 ≈ 150 μM),
21
ﬂavonoids showing low
micromolar inhibition22 and the development of a hit from
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Figure 1. Structure of cADPR and N9-butyl analogs.
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commercial libraries generating the most active reported
noncovalent inhibitor to date (IC50 = 4.7 μM).
23
As both cADPR and ADPR are derived from a common
intermediate,24 we chose to design product-like inhibitors based
on the cADPR structure to exploit inhibition of CD38 cADPR
hydrolase activity. cADPR itself is unattractive for inhibitor
design, since it is hydrolyzed at the N1 link in both neutral
aqueous solution and under physiological conditions.25−27
More stable analogs have been accessed by one of two routes:
either a chemoenzymatic route modeled on the biosynthesis of
cADPR from NAD+ or by total chemical synthesis. We have
previously reported a chemoenzymatic route to N1-cyclic
inosine 5′-diphosphate ribose (cIDPR, 2) via its 8-bromo
derivative (8-Br-cIDPR, 3, Figure 1).28 Chemically and
biologically stable, 2 and 3 both inhibit cADPR hydrolysis by
the catalytic domain of CD38 (shCD38; IC50 of 276 and 158
μM, respectively). Furthermore, 2 acts as an agonist for Ca2+-
release with almost equivalent potency to cADPR in
permeabilized T-cells and 3 is a membrane permeant
agonist.29,30
Until recently, total synthetic approaches have required
modiﬁcation of the “northern” ribose to generate a more stable
N1-link by introduction of a carbocyclic “northern” ribose,31−33
replacement of the “northern” ribose, or both ribose sugars, by
an alkyl or ether bridge34,35 or by attaching the “northern”
ribose to the base at C-2″.36 We recently reported the use of
modiﬁed Vorbrüggen conditions to eﬀect stereo- and
regiospeciﬁc introduction of an acetylated ribose at the N1-
position of a protected inosine and demonstrated the utility of
this method in the ﬁrst total synthesis of 3.37 This paves the
way for further exploration of the structure−activity relation-
ship (SAR) of cADPR, using the cIDPR template, with the
opportunity to retain an intact “northern” ribose and without
the structural limitations of using enzymatic cyclization.38 We
report here the synthesis of the ﬁrst analogs in which the
“southern” ribose is selectively replaced, the activity of these
analogs as inhibitors of cADPR hydrolysis by shCD38,
crystallography of the most potent inhibitor with shCD38,
and HPLC studies to examine the ability of shCD38 to
hydrolyze the cIDPR scaﬀold.
■ RESULTS AND DISCUSSION
Crystallography of shCD38 has revealed the mechanism by
which NAD+ is either cyclized to cADPR or hydrolyzed to
ADPR.39−41 Crystal structures obtained with shCD38 and
unnatural ligands 2 (PDB code 2PGJ),42 cyclic adenosine 5′-
diphosphate carbocyclic ribose (cADPcR, 3UHI),43 and 8-
NH2-cIDPR (3U4H) suggest a critical role for the base and
“northern” ribose in the binding of cADPR analogs to CD38, as
might be predicted for the locus of both cADPR formation and
degradation. Glu146 hydrogen-bonds to N6 and N7 and is
critical in regulating the ADPRC multifunctionality.44 Glu226 is
the catalytic residue and interacts with the 2″- and 3″-OH of
the “northern” ribose.45 It has recently been highlighted as
crucial in orientating NAD+ for cleavage of nicotinamide.46 The
“southern” ribose appears to be accommodated in a more
ﬂexible fashion across the open face of the pocket. Thus, we
designed analogs in which the “southern” ribose is replaced
with an N9-butyl linker (N9-butyl-cIDPRs 4−7, Figure 1) to
explore whether it is required for binding to CD38. Such
analogs would be predicted to have the further advantage that
the acid sensitivity of the N9-ribosyl link is eliminated.47
Molecular Modeling. To predict the binding mode of
analogs 4−7, which might be more ﬂexible because of the linear
N9-alkyl chain, they were ﬁrst docked into the 2PGJ crystal
structure of shCD38 in complex with cIDPR. The docked and
minimized pose was almost identical to that of cIDPR (Figure
2A), suggesting that these analogs would mimic the critical
interactions with the binding site. Minimization of the protein
resulted in very little movement of the amino acid residues
forming the binding site.
The docked ligands display face-to-face stacking between the
hypoxanthine base and Trp189. There is one predicted
hydrogen bond from the ribose 3′-OH a hydroxyl group to
the catalytic acid (Glu226), although the 2′-OH does not
appear to be as closely located, and from the side chains of
Ser126 and Arg127 to the phosphates. The 8-amino group of 7
is predicted to form an additional hydrogen bond to the side
chain of Asp155. The N9-butyl chain of the docked ligand lies
across the entrance of the binding pocket in an almost identical
position to the “southern” ribose of cIDPR (Figure 2B).
Synthesis of N9-Butyl-cIDPR Analogs 4−7. 6-Chlor-
opurine (11, Scheme 1) was alkylated with 4-chlorobutylacetate
Figure 2. N9-Butyl-cIDPR docked into 2PGJ crystal structure. Comparison between 2PGJ crystal structure of N1-cIDPR (carbons in cyan) bound to
shCD38 and (A) docked N9-butyl cIDPR 4 (carbons in yellow) showing overlap of their structures in the binding pocket; (B) interaction of 8-NH2-
N9-butyl cIDPR 7 (carbons in pink) with critical residues in the binding pocket and additional predicted H-bond to Asp155.
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in the presence of 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU).48
The desired major product, the N9-isomer 12, was obtained in
high yield after separation from the minor N7-isomer.
Treatment of 12 with methanolic ammonia at 80 °C eﬃciently
eﬀected both amination at the 6-position and deprotection of
the N9-butyl acetyl ester to aﬀord N9-hydroxybutyladenine
13.49 The alkyl group was then reprotected as the TBDPS ether
using tert-butyldiphenylsilyl chloride (TBDPS-Cl) and imiza-
dole to give 14. Introduction of the 8-bromo substituent to 14
is crucial at this stage to promote the subsequent N1-
ribosylation.37 Attempted bromination of 14 using a solution
of bromine in sodium hydrogen phosphate buﬀer and dioxane
was not successful, and no reaction was observed. Similarly,
treatment of 14 with N-bromosuccinimide or N-bromoaceta-
mide aﬀorded only starting material. Applying the conditions
developed by Laufer et al.50 for the 8-bromination of N9-
methyl chloropurines, we ﬁrst deprotonated 14 using lithium
diisopropylamide (LDA), followed by addition of 1,2-
dibromotetrachloroethane.51 On a small scale (100 mg) the
desired 8-brominated product 15 was isolated in 67% yield.
However, when this reaction was scaled up (2.5 g), an
inseparable mixture of two products was obtained after column
chromatography. Mass spectrometry (m/z = 480.1970 and
524.1476) containing characteristic 35/37Cl and 79/81Br isotope
patterns conﬁrmed this was both the 8-bromo and 8-chloro
substituted products. It was only possible to recover the starting
material by treating the mixture of products with Pd/C under
an atmosphere of H2. We therefore sought an alternative source
of bromine that would avoid this complication and found that
direct addition of Br2 to deprotonated 14 generated 15 in 66%
yield, with the remainder as starting material, which could be
separated by column chromatography and reused. Treatment of
15 with excess sodium nitrite converted 8-bromoadenine 15 to
8-bromohypoxanthine 16, which was a suitable substrate for
N1-ribosylation. Deprotonation of 16 with DBU followed by
addition of tetraacetyl-D-ribose and trimethylsilyl triﬂate (TMS-
OTf)37 aﬀorded stereo- and regioselective N1-coupling to
generate only the desired N1-ribosylated product 17 in high
yield. Deprotection of the three acetyl esters using methanolic
ammonia generated triol 18.
The 2′,3′-diol was reprotected as an isopropylidene ketal to
aﬀord 19, which allowed selective introduction of the ﬁrst
phosphate ester to the 5′-OH by treatment of 19 with N,N-
diisopropyldibenzylphosphoramidite and 5-phenyl-1-H-tetra-
zole as activator, followed by oxidation of the intermediate
phosphite with hydrogen peroxide and triethylamine (Scheme
2). The silyl ether of 20 was then removed under neutral
conditions to reveal the hydroxyl group. The second protected
phosphate ester was introduced by treatment of 21 with
cyclohexylammonium S,S-diphenylphosphorodithioate (PSS),
2,4,6-triisopropylbenzenesulfonyl chloride (TPS-Cl), and 5-
phenyl-1-H-tetrazole in pyridine under strictly dry conditions
to generate the fully protected precursor for cyclization, 22.
Sequential deprotection of the phosphates was carried out as
previously described37 using ﬁrst 50% aqueous TFA to
simultaneously remove the tert-butyl esters and the isopropy-
lidene ketal, then 0.1 M sodium hydroxide in dioxane, to aﬀord
24. The N9-butyl chain shows increased stability toward acidic
conditions, compared to the natural “southern” ribose of
cIDPR, which had initially suﬀered partial hydrolysis at the N9-
glycosidic bond during deprotection of the isopropylidene
acetals and tert-butyl phosphate esters.37,47 No degradation of
the N9-butyl analogs was observed even over prolonged
periods in 50% TFA at room temperature, since the ribose
oxygen has been removed.
Cyclization of 24 was promoted using iodine and activated 3
Å molecular sieves in pyridine,33 under very dilute conditions,
to aﬀord 5 (21% yield over two steps, Scheme 3). Because of
the stability of our cIDPR-based analogs, modiﬁcations at the 8-
position were possible after cyclization, which allowed us to
generate three further analogs; 8-H, 8-N3, and 8-NH2.
Subjecting 5 to an atmosphere of hydrogen with Pd/C catalysis
generated the 8-H analog, N9-butyl-cIDPR (4). Treatment of 5
Scheme 1. Synthesis of the N1-Ribosyl-N9-butyl-8-
bromohypoxanthine Building Blocka
aReagents: (i) DBU, 4-Cl-butyl-OAc, 77%; (ii) NH3, MeOH, 96%;
(iii) imidazole, TBDPS-Cl, 92%; (iv) (a) diisopropylamine, n-BuLi,
(b) Br2, 66%; (v) NaNO2, AcOH (aq), 84%; (vi) (a) DBU, (b)
tetraacetyl-D-ribose, TMSOTf, 86%; (vii) NH3, MeOH, 98%.
Scheme 2. Sequential Introduction of the Phosphate Estersa
aReagents: (i) pTsOH, H3CC(OMe)2CH3, acetone, 100%; (ii) (a)
(tBuO)2PN(
iPr)2, 5-Ph-1H-tetrazole, DCM; (b) H2O2, Et3N, 80%;
(iii) TBAF·3H2O, AcOH, 100%; (iv) PSS, TPS-Cl, 5-Ph-1H-tetrazole,
pyridine, 100%; (v) 50% TFA (aq), 100%; (vi) 0.1 M NaOH−dioxane.
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with NaN3 in an attempt to generate the 8-N3 analog 6 was not
successful, despite conversion to the triethylamine salt or the
free acid to improve the solubility of 5 in DMF. In each case,
the DMF solution became cloudy over time as the sodium salt
of the starting material was formed and became insoluble in the
reaction media. However, upon treatment of the free acid form
of 5 with TMSN3 in DMF, no precipitation was observed and
the clear solution was stirred at 70 °C for 16 h, becoming
yellow in color as the reaction proceeded. The reaction
progression was followed by RP-HPLC which clearly showed
the shift in wavelength as the 8-bromo starting material (λmax =
255 nm) was converted into the 8-azido product [8-N3-N9-
butyl-cIDPR (6), λmax = 277 nm]. Treatment of 6 with
dithiothreitol reduced the 8-azido substituent to an 8-amino
group which gave 8-NH2-N9-butyl-cIDPR (7).
Inhibition of CD38-Mediated cADPR Hydrolysis. The
ability of the novel compounds 4−7 to inhibit shCD38-
mediated hydrolysis of cADPR was assessed in a dose−
response manner using a ﬂuorimetric cycling assay.52 cIDPR
(2) inhibits hydrolysis of cADPR with an IC50 of 276 μM.
42
The novel N9-butyl analogs 4−7 inhibit cADPR hydrolysis in a
concentration-dependent manner, with half maximal inhibition
in the low micromolar range (Figure 3 and Table 1). They are
all more potent than 2, showing an almost 100-fold increase in
inhibition. The introduction of an 8-bromo substituent (5)
gave a marginally improved inhibition (IC50 = 27 μM)
compared to the parent 4 (33 μM), which was then further
improved by substitution to the 8-azido (6) or 8-amino (7)
group (IC50 of 6.4 and 3.3 μM, respectively). The trend of
improved inhibition upon 8-H → 8-Br → 8-NH2 substitution
mimics that which was observed for the cIDPR series,43 the 8-
NH2 derivative beneﬁting from an additional binding site
interaction with Asp155. This suggests that the new analogs are
binding similarly in the active site (vide infra). They are of
comparable potency to the recently reported non-nucleoside
and ﬂavonoid NADase inhibitors.22,23 The improved inhibition
of cADPR hydrolysis suggests that the “southern” ribose is not
essential for activity.
The signiﬁcant increase in potency by substitution of the
“southern” ribose with a butyl chain may be a result of the
increased ﬂexibility aﬀorded by an alkyl chain linker, compared
to a ribose sugar. This might allow the ligand to align other key
residues more favorably with their binding targets, resulting in a
tighter aﬃnity for CD38. Another factor may be the
hydrophobic nature of the butyl chain, which may prefer to
sit further into the binding pocket, in a less polar environment
away from bulk solvent.
Structure of 8-NH2-N9-butyl-cIDPR (7) Complexed
with Wild-Type CD38. Preformed crystals of wild-type
shCD38 were soaked with a cryoprotectant solution containing
5 mM 8-NH2-N9-butyl-cIDPR (7). X-ray diﬀraction data were
collected to a resolution of 2.05 Å. The structure was solved by
the molecular replacement method revealing two molecules of
CD38 in the asymmetric unit with a ligand present in each
active site (Figure 4A). Previous crystallographic work43 has
generally shown occupancy of only one site by noncovalent
inhibitors.
To our surprise, the electron density within each active site
did not ﬁt the cyclic compound 7. However, hydrolysis at N1 to
generate a linear compound, 7a, gave a structure with a good ﬁt
(Figure 4B). After reﬁnement, the complex clearly showed that
the catalytic residue Glu226 was still hydrogen-bonded to the
ribose. For molecule A, Glu226 H-bonds to the 1′- and 3′-OH
of the ribose (both 2.7 Å), which has previously been observed
in hydrolyzed intermediates or products.53 In molecule B,
Glu226 forms H-bonds with the 3′-OH (2.6 Å) and longer
distance interactions with the 1′-OH and 2′-OH (3.3 and 3.5
Å). In both molecules, the 2′-OH interacts with an active site
water molecule (Figure 4C). Addition of water to C-1′ has
occurred to generate the hydrolyzed product, and the -OH
group is attached to the α-face of the ribose, as has been
observed previously for NAD+ hydrolysis products captured by
crystallization.53,54 Such observations are at odds with both the
proposed ionic or covalent hydrolysis mechanisms, which
predict a predominantly or entirely β-product, respectively.55
Scheme 3. Synthesis of N9-Butyl-cIDPR Analogs 4−7a
aReagents: (i) I2, 3 Å molecular sieves, pyridine, 21%; (ii) H2, Pd/C,
NaHCO3, EtOH−H2O, 76%; (iii) TMSN3, 57%; (iv) dithiothreitol,
0.05 M TEAB, 68%.
Figure 3. Inhibition of shCD38-mediated cADPR hydrolysis by
analogs 4−7.
Table 1. Half Maximal Values for Inhibition of shCD38-
Mediated cADPR Hydrolysis by Novel Analogs 4−7 and
Equivalent 8-Substituted cIDPRs
cIDPR IC50 (μM)
43 N9-butyl-cIDPR IC50 (μM)
8-H 2 276 4 33
8-Br 3 158 5 27
8-N3 6 6.4
8-NH2 56 7 3.3
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm501037u | J. Med. Chem. 2014, 57, 8517−85298520
Notably, the hydrolyzed ligand still occupies the catalytic site in
the same manner as the cADPR, except that the hypoxanthine
base has rotated in the binding pocket after hydrolysis. While
maintaining the stacking interaction with Trp189, it has also
formed new hydrogen bonds with Glu146 and Asp156 via its 8-
NH2 and 6-O substituents, respectively (Figure 4C). It is
unusual to capture this snapshot of the ligand directly after
hydrolysis, before diﬀusion out of the binding site. Previously
reported crystal structures of the hydrolysis products of N7-
cGDPR and cADPR, GDPR and ADPR, respectively, have also
captured products that were not bound in a conformation
directly resulting from hydrolysis.53
Proposed Mechanism of Hydrolysis by CD38. Finding a
hydrolyzed ligand in the active site of CD38 was unexpected, as
the cIDPR template has previously been considered “non-
hydrolyzable”.42 The absence of a partial positive charge at N1,
compared to that in the N6-amino form of cADPR, was
thought to contribute to this stability (Figure 5).
However, a mechanism in which the anomeric oxygen assists
in breaking the N1-link could still be envisaged (Scheme 4).
This would be without prejudice as to whether the role of
Glu226 is to capture the resulting oxonium ion formally or
interact with it as an ion pair before insertion of water to
generate the ﬁnal linear product. Examination of the crystal
structures 2PGJ and 3U4H suggests that both binding sites
Figure 4. Crystal structure of PDB code 4TMF. (A) Ligand (shown as sticks) occupies each active site. (B) The electron density ﬁts that of a
hydrolyzed ligand (carbons in cyan, key residues that interact with the ligand in the binding site shown as green sticks). (C) H-bonds (shown as
black dotted lines) are formed between the rotated hypoxanthine base and both Glu146 and the backbone nitrogen of Asp156. Interacting residues
are shown as pink sticks, and other residues are shown as green lines. The interacting binding site water is shown as a red sphere, and the other
waters as red crosses.
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contain two water molecules close to the N1-link of the cyclic
ligand. One of these waters forms H-bonds to Leu123, Leu145,
and the ribose 2′-OH that is consistent with other reported
CD38 crystal structures.54 Notably, in the 3U4H crystal with 8-
NH2-cIDPR, the remaining water molecule lies within 3 Å of
the hypoxanthine carbonyl group. This water is not observed in
the complex of the hydrolyzed ligand 7a (PDB code 4TMF);
thus, we postulate that donation of a proton from this water
molecule could be enzyme-assisted in the active site. Further
examination reveals a proximal histidine residue (His133) that
may potentially contribute to overall catalysis (Figure 6).
For the corresponding cADPR ligand to be hydrolyzed via
such a mechanism would require the ligand to be present in the
N6-imino form. Indeed, an earlier report indicated that cADPR
exists in two forms, the N6-imino and N6-amino, the latter with
a pKa of 8.3.
56 Although at physiological pH the amino form
will be predominant, the active form for Ca2+ release remains
unresolved and crystallization of cADPR originally suggested
that the C6−N6 bond displayed double bond characteristics
(length 1.33 Å, cf. 1.47 Å expected for an amino group) with
only one hydrogen atom bound to N6.2 This is somewhat
surprising given that the molecule was crystallized as its free
acid, presumably well below pH 8.3. The C6−N6 bond length
in the cADPcR-shCD38 complex,43 the only cocrystal structure
of a cyclic ligand with a starting C6-substituent in the amino
form yet determined, measures 1.35 Å, also suggesting
substantial double bond character. The authors measured the
pKa of the N6-amino dissociation in this case as 8.9.
26 However,
cADPcR is a completely nonhydrolyzable ligand due to the
absence of the ribose oxygen. Since crystallization of cADPR
itself with shCD38 is not possible because of its very rapid
hydrolysis, it has been impossible to capture directly the
intermediates in this process. Previously, the surrogate substrate
NGD+ revealed the role of Glu226 in activating and stabilizing
the intermediate precursor for hydrolysis or cyclization.53 We
originally showed that cIDPR, as expected, has no ionization
between 6.8 and 10.9 28 and it is not likely that 7 will be any
Figure 5. cADPR has a partial positive charge at N1.
Scheme 4. Proposed Mechanism for Hydrolysis of 7 by a High Concentration of shCD38
Figure 6. Docking of 8-NH2-N9-butyl-cIDPR (7) into 3U4H after
removal of ligand (ligand carbons in pink sticks, protein carbons in
green).
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diﬀerent. Thus, since it is unlikely that cIDPR or any related
analog will exist in the 6-phenolic form at the pH used with
shCD38 (vide infra) and the enzyme would not adopt a
diﬀerent mechanism to hydrolyze an analog vs cADPR itself, we
can conclude that the complex of 7a with shCD38 provides the
ﬁrst evidence that CD38 can bind cADPR in the N6-imino
form. This could have future implications for inhibitor design.
We clearly cannot comment upon the ability of CD38 to bind
the N6-amino form of cADPR.
Study of Ligand Hydrolysis by CD38. Following the
discovery of hydrolyzed ligand 7a in the crystal complex, it was
important to determine whether it is the cyclic or the
hydrolyzed linear compound that inhibits hydrolysis of
cADPR by shCD38. Incubation of 7 (1 mM ﬁnal
concentration) with 4 mg/mL shCD38 was monitored using
RP-HPLC. The peak corresponding to 7 (tR = 9.1 min)
reduced in intensity over time, alongside the appearance of a
new peak (tR = 10.6 min), which was characteristic of an ADPR
analog (see Supporting Information, Figure S1). The rate of
conversion depended on the concentration of CD38 present in
solution (Figure S2), and no change in the original peak was
observed in a parallel control experiment containing no
shCD38 (data not shown). Novel analogs 4, 5 and cIDPR
(2) were also analyzed in this way (Figure 7). Surprisingly, we
found that all the compounds, including cIDPR, are hydrolyzed
by the enzyme at 4 mg/mL but at a slower rate than 7. The
increased rate of hydrolysis of 7 could conceivably be promoted
by the additional hydrogen bond generated between the 8-NH2
substituent and Asp155 promoting elongation of the N1-bond
toward the transition state. This faster hydrolysis of 7 under
these conditions (50% hydrolysis for 7 at T = 105 min and for
cIDPR at T = 420 min), also reinforced by the extra interaction
aﬀorded by the 8-amino group after cleavage, perhaps explains
why the hydrolyzed ligand 7a is captured in the 8-NH2-N9-
butyl-cIDPR:CD38 complex, but a cyclic ligand is observed in
the previously reported cIDPR:CD38 complex 2PGJ.42
These conditions are representative of crystallization
concentrations of shCD38 (10 mg/mL) and are 10 000-fold
more concentrated than those used in the enzyme assay (1 μg/
mL). Therefore, further HPLC experiments were carried out
using shCD38 concentrations of 1 μg/mL and either cIDPR or
7 to observe the eﬀect of CD38 under conditions that reﬂect
the enzyme assay (Supporting Information, Figure S3). Under
these conditions the ligand is not hydrolyzed, conﬁrming that
the inhibition observed in the CD38 assay is a consequence of
the cyclic compounds, not their hydrolyzed counterparts.
■ CONCLUSION
Two of the analogs developed in this study are potent (≤10
μM) inhibitors of cADPR hydrolysis by CD38. Analogs 4−7
illustrate that the “southern” ribose can be modiﬁed to
considerably improve inhibitory activity of CD38 mediated
cADPR hydrolysis. This agrees with modeling predictions
based on the shCD38-ligand crystal structure complex
interactions and conﬁrms that the “northern” ribose and base
are key features for the interaction of cADPR analogs with the
CD38 binding pocket. The investigation of SAR in this region
in isolation was not possible prior to development of a method
for N1-ribosylation. This method thus opens up new avenues
and the potential to introduce desirable characteristics, such as
membrane permeability, into cADPR analogs by modiﬁcations
in this region, without loss of activity at CD38. Crystallization
of 8-NH2-N9-butyl-cIDPR with shCD38 revealed that the
cIDPR scaﬀold can unexpectedly be hydrolyzed at high
concentrations of shCD38, resulting in a cocrystal structure
with linear 8-NH2-N9-butyl-IDPR (7a) in the active site.
Hydrolysis of the hypoxanthine-linked scaﬀold oﬀers new
insight into the mechanism by which CD38 hydrolyzes cADPR
to ADPR and suggests for the ﬁrst time that the imino form is
active in this process. However, HPLC studies suggest that
hydrolysis would not occur under assay or physiologically
relevant concentrations. Thus, this observation does not detract
from the established use of cIDPR or its derivatives as either
pharmacological tools or as nonhydrolyzable templates for
future CD38 inhibitor design or indeed of 8-Br-cIDPR (3)30 as
a stable membrane permeant agonist of Ca2+ release.
■ EXPERIMENTAL SECTION
General. All reagents and solvents were of commercial quality and
were used without further puriﬁcation, unless described otherwise.
Unless otherwise stated, all reactions were carried out under an inert
atmosphere of argon. 1H, 13C, and 31P NMR spectra were collected on
a Varian Mercury 400 MHz or Bruker Avance III 500 MHz
spectrometer. All 1H and 13C NMR assignments are based on
gCOSY, gHMBC, gHSQC, and DEPT-135 experiments. Abbrevia-
tions for splitting patterns are as follows: b, broad; s, singlet; d,
doublet; t, triplet; m, multiplet. Coupling constants are given in hertz
(Hz). High resolution time-of-ﬂight mass spectra were obtained on a
Bruker Daltonics micrOTOF mass spectrometer using electrospray
ionization (ESI). The purity of new tested compounds was determined
to be ≥95% by analytical HPLC. Analytical HPLC analyses were
carried out on a Waters 2695 Alliance module equipped with a Waters
2996 photodiode array detector (210−350 nm). The chromatographic
system consisted of a Hichrom Guard column for HPLC and a
Phenomenex Synergi 4 μm MAX-RP 80A column (150 mm × 4.60
mm), with elution at 1 mL/min with the following ion-pair buﬀer:
0.17% (m/v) cetrimide and 45% (v/v) phosphate buﬀer (pH 6.4) in
MeOH. Synthetic phosphates were assayed and quantiﬁed by the
Ames phosphate test.57
6-Chloro-9-(4-acetoxybutyl)purine (12).48 To 6-chloropurine
11 (2.50 g, 16.2 mmol) and DBU (2.91 mL, 19.4 mmol) in DMF (22
mL) was added 4-chlorobutylacetate (4.54 mL, 32.3 mmol). After the
mixture was stirred at 60 °C for 14 h, the DMF was removed under
reduced pressure, and the residue was puriﬁed by column
chromatography on silica gel, eluting with PE/EtOAc (1:0 → 0:1 v/
v) to aﬀord the title compound (3.07 g, 71%) as a colorless oil. Rf =
0.61 (DCM/MeOH 9:1 v/v); 1H NMR (400 MHz, MeOD) δ 8.78 (s,
Figure 7. Hydrolysis of analogs 4, 5, 7, and cIDPR (2) over time with
shCD38 (4 mg/mL).
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1H), 8.16 (s, 1H), 4.37 (t, 2H, J = 7.2, CH2), 4.15 (t, 2H, J = 6.4,
CH2), 2.08−2.04 (m, 5H, CH2 and OAc), 1.74−1.67 (m, 2H, CH2)
ppm.
9-(4-Hydroxybutyl)adenine (13).49 A solution of 12 (3.00 g,
11.2 mmol) in MeOH (7 mL) was cooled to 0 °C and saturated with
NH3 (g), then stirred for 14 h at 80 °C. On cooling, a white solid
precipitated, which was collected by ﬁltration and air-dried to aﬀord
the title compound (2.22 g, 96%). Rf = 0.17 (DCM/MeOH 9:1 v/v);
1H NMR (400 MHz, MeOD) δ 8.23 (s, 1H), 8.16 (s, 1H), 4.30 (t, 2H,
J = 7.2, CH2), 3.61 (t, 2H, J = 6.4, CH2), 2.03−1.96 (m, 2H, CH2),
1.61−1.54 (m, 2H, CH2) ppm; HRMS (ESI+) calcd for C9H14N5O1
208.1193 [(M + H)+], found 208.1195.
9-(4-tert-Butyldiphenylsilylbutyl)adenine (14). To 13 (2.00 g,
9.65 mmol) in DMF (20 mL) were added imidazole (1.71 g, 25.09
mmol) and TBDPS-Cl (3.25 mL, 12.55 mmol). After 14 h at rt, all
solvents were evaporated and the residue was puriﬁed by column
chromatography on silica gel, eluting with DCM/acetone (1:0 → 0:1
v/v) to aﬀord the title compound (3.96 g, 92%) as a white solid. Rf =
0.42 (DCM/acetone 1:3 v/v); 1H NMR (400 MHz, CDCl3) δ 8.21 (s,
1H), 8.09 (s, 1H), 7.62−7.60 (m, 4H), 7.43−7.35 (m, 6H), 4.26 (t,
2H, J = 7.0, CH2), 3.71 (t, 2H, J = 6.2, CH2), 2.05−1.97 (m, 2H,
CH2), 1.58−1.52 (m, 2H, CH2), 1.01 (s, 9H) ppm; 13C NMR (100
MHz, CDCl3) δ 155.3, 153.0, 150.2, 140.5, 135.5 (4C), 133.7 (2C),
129.7 (2C), 127.7 (4C), 119.8, 63.0, 43.8, 29.5, 26.9 (3C), 26.7, 19.2
ppm; HRMS (ESI+) calcd for C25H32N5OSi 446.2371 [(M + H)
+],
found 446.2377.
9-(4-tert-Butyldiphenylsilylbutyl)-8-bromoadenine (15). To
diisopropylamine (4.67 mL, 33.32 mmol) in THF (20 mL) at −78 °C
was added n-butyllithium (21.2 mL, 1.6 M solution, 33.97 mmol),
dropwise. After 1 h, a solution of 14 (2.97 g, 6.66 mmol) in THF (25
mL) was added dropwise and stirring continued for a further 1 h. Br2
(2.04 mL, 39.96 mmol) was added dropwise and the solution allowed
to warm to rt over 4 h. The reaction was quenched by addition of NH4
(aq, 2 mL), and all solvents were evaporated. The residue was taken up
in DCM/H2O (1:1 v/v, 100 mL) and the organic layer separated,
washed with brine, dried (Na2SO4), and evaporated to dryness. The
crude material was puriﬁed by column chromatography on silica gel,
eluting with DCM/acetone (1:0 → 0:1 v/v) to aﬀord the title
compound (2.18 g, 62%) as an amorphous cream solid. Rf = 0.61
(DCM/acetone 1:1 v/v); 1H NMR (400 MHz, MeOD) δ 8.31 (s, 1H,
H-2), 7.64−7.62 (m, 4H), 7.40−7.33 (m, 6H), 5.85 (bs, 2H, NH2),
4.22 (t, 2H, J = 7.4, CH2), 3.70 (t, 2H, J = 6.1, CH2), 2.00−1.93 (m,
2H, CH2), 1.62−1.55 (m, 2H, CH2), 1.03 (s, 9H) ppm; 13C NMR
(100 MHz, CDCl3) δ 154.2, 153.0, 151.3, 135.5 (4C), 133.7 (2C),
129.6 (2C), 127.8 (4C), 127.3, 119.9, 63.0, 44.4, 29.4, 26.8 (3C), 26.1,
19.1 ppm; HRMS (ESI+) calcd for C25H31N5OSi
79Br 524.1476 [(M +
H)+], found 524.1473, calcd for C25H31N5OSi
81Br 526.1455 [(M +
H)+], found 526.1462.
9-(4-tert-Butyldiphenylsilylbutyl)-8-bromohypoxanthine
(16). To 15 (4.13 g, 7.87 mmol) in AcOH/H2O (20:3 v/v, 138 mL)
was added NaNO2 (6.52 g, 94.48 mmol) in one portion. After 48 h, all
solvents were evaporated and EtOH (100 mL) was added and
evaporated to dryness. The residue was taken up in CHCl3 and washed
with H2O, then NaHCO3 (aq sat.) to pH 7. The organic layer was
washed with brine, dried (Na2SO4), and evaporated to dryness. The
crude material was puriﬁed by column chromatography on silica gel,
eluting with PE/EtOAc (1:0 → 0:1 v/v) to aﬀord the title compound
(3.49 g, 84%) as a cream foam. Rf = 0.37 (PE/EtOAc 1:3 v/v);
1H
NMR (400 MHz, CDCl3) δ 13.07 (bs, 1H, NH), 8.16 (s, 1H, 2H),
7.65−7.63 (m, 4H), 7.41−7.34 (m, 6H), 4.21 (t, 2H, J = 7.3, CH2),
3.71 (t, 2H, J = 6.0, CH2), 1.96 (tt, 2H, J = 7.4, 7.3, CH2), 1.58 (tt, 2H,
J = 6.5, 6.0, CH2), 1.04 (s, 9H) ppm;
13C NMR (100 MHz, CDCl3) δ
158.0, 150.6, 145.5, 135.6 (4C), 133.8 (2C), 129.7 (2C), 127.7 (4C),
126.3, 124.8, 63.0, 44.8, 29.4, 26.9 (3C), 26.2, 19.2 ppm; HRMS
(ESI+) calcd for C25H30N4O2Si
79Br 525.1316 [(M + H)+], found
525.1319, calcd for C25H30N4O2Si
81Br 527.1295 [(M + H)+], found
527.1301.
N1-(2′,3′,5′-Tri-O-acetyl-β-D-ribofuranosyl)-N9-[4-(tert-
butyldiphenylsilyl)oxybutyl)-8-bromohypoxanthine (17). Inter-
mediate 16 (400 mg, 0.761 mmol) was taken up in DCM (4.0 mL),
and DBU (341 μL, 2.283 mmol) was added. After 30 min, 1,2,3,5-
tetra-O-acetyl-β-D-ribofuranose (266 mg, 0.837 mmol) was added and
the solution cooled to −78 °C. Trimethylsilyl triﬂuoromethanesulfo-
nate (551 μL, 3.044 mmol) was added dropwise and the solution
stirred for a further 45 min before warming to rt. After 1 h, NaHCO3
(sat. aq.) was added and the crude material extracted into DCM (×3).
The combined organic fractions were dried (Na2SO4), and solvent was
evaporated under reduced pressure. The residue was puriﬁed by
column chromatography on silica gel, eluting with PE/EtOAc (1:0 →
1:0 v/v) to aﬀord the title compound (203 mg, 90%) as a colorless
glass. Rf = 0.69 (PE/EtOAc 1:3 v/v);
1H NMR (400 MHz, CDCl3) δ
8.14 (s, 1H, 2H), 7.63 (dd, 4H, J = 7.8, 1.5), 7.40−7.34 (m, 6H) (10 ×
Ar-H), 6.39 (d, 1H, J = 4.6, H-1′), 5.47 (dd, 1H, J = 5.8, 4.6, H-2′),
5.44 (dd, 1H, J = 5.8, 4.5, H-3′), 4.42−4.38 (m, 3H, H-4′ and both H-
5′), 4.17 (t, 2H, J = 7.3, CH2), 3.70 (t, 2H, J = 6.0, CH2), 2.13 (s, 3H),
2.11 (s, 3H), 2.07 (s, 3H) (3 × OAc), 1.96−1.92 (m, 2H, CH2), 1.58−
1.54 (m, 2H, CH2), 1.03 (s, 9H) ppm;
13C NMR (100 MHz, CDCl3)
δ 170.2, 169.58, 169.57, 154.8, 148.7, 144.1, 135.5 (4C), 133.7 (2C),
129.7 (2C), 127.7 (4C), 126.1, 124.1, 87.3, 80.3, 74.2, 70.3, 63.0, 62.9,
44.7, 29.4, 26.9 (3C), 26.3, 20.8, 20.5, 20.4 19.2 ppm; HRMS (ESI+)
calcd for C36H44N4O9Si
79Br 783.2055 [(M + H)+], found 783.2046,
calcd for C36H44N4O9Si
81Br 785.2035 [(M + H)+], found 785.2042.
N1-(β-D-Ribofuranosyl)-N9-[4-(tert-butyldiphenylsilyl)-
oxybutyl)-8-bromohypoxanthine (18). Intermediate 17 (600 mg,
0.766 mmol) was taken up in MeOH (6 mL) in a pressure tube. The
solution was saturated with NH3 (g) at 0 °C, then stirred at rt for 12 h.
The solvent was evaporated and the residue puriﬁed by column
chromatography on silica gel, eluting with PE/EtOAc (1:0→ 1:0 v/v)
to aﬀord the title compound (492 mg, 98%) as a white amorphous
solid. Rf = 0.35 (DCM/acetone 1:1 v/v);
1H NMR (500 MHz,
MeOD) δ 8.79 (s, 1H, H-2), 7.62−7.60 (m, 4H), 7.42−7.35 (m, 6H)
(10 × Ar-H), 6.22 (d, 1H, J = 3.1, H-1′), 4.32−4.28 (m, 2H, H-2′, H-
3′), 4.23 (t, 2H, J = 7.1, CH2), 4.13 (ddd, 1H, J = 5.5, 2.9, 2.5, H-4′),
3.98 (dd, 1H, J = 12.3, 2.5, H-5a′), 3.83 (dd, 1H, J = 12.3, 2.9, H-5b′),
3.70 (t, 2H, J = 6.0, CH2), 1.98−1.92 (m, 2H, CH2), 1.55−1.49 (m,
2H, CH2), 1.02 (s, 9H) ppm;
13C NMR (125 MHz, MeOD) δ 156.9,
150.5, 147.1, 136.6 (4C), 134.8 (2C), 130.9 (2C), 128.8 (4C), 127.7,
124.6, 91.5, 86.2, 76.9, 70.6, 64.1, 61.7, 45.7, 30.4, 27.4 (3C), 27.1, 19.9
ppm; HRMS (ESI+) calcd for C30H38N4O6Si
79Br 657.1739 [(M +
H)+], found 657.1747, calcd for C30H38N4O6Si
81Br 659.1718 [(M +
H)+], found 659.1729.
N1-(2′,3′-O-Isopropylidine-β-D-ribofuranosyl)-N9-[4-(tert-
butyldiphenylsilyl)oxybutyl)-8-bromohypoxanthine (19). To
18 (430 mg, 0.634 mmol) in acetone/2,2-dimethoxypropane (5 mL,
4:1 v/v) was added p-TsOH (124 mg, 0.634 mmol). After 30 min,
DCM and NaHCO3 (sat. aq) were added, the organic layer was dried
(Na2SO4), and all solvents were evaporated. The residue was taken up
in MeOH (2 mL), and Dowex 50WX8 H+ resin (50 mg) was added.
After 30 min the resin was removed by ﬁltration under gravity and the
solvent evaporated to obtain the title compound (455 mg, 100%) as a
colorless glass. Rf = 0.63 (PE/EtOAc 1:3 v/v);
1H NMR (400 MHz,
CDCl3) δ 7.87 (s, 1H, H-2), 7.55 (dd, 4H, J = 5.9, 1.5), 7.35−7.26 (m,
6H) (10 × Ar-H), 5.62 (d, 1H, J = 2.8, H-1′), 5.23 (dd, 1H, J = 6.5,
2.8, H-2′), 5.08 (dd, 1H, J = 6.5, 3.6, H-3′), 4.28 (dd, 1H, J = 3.6, 2.4,
H-4′), 4.09 (t, 2H, J = 7.3, CH2), 3.85 (dd, 1H, J = 12.2, 2.4, H-5a′),
3.75 (bd, 1H, J = 12.2, H-5b′), 3.61 (t, 2H, J = 6.0, CH2), 1.89−1.82
(m, 2H, CH2), 1.52 (s, 3H), 1.50−1.45 (m, 2H, CH2), 1.28 (s, 3H),
1.02 (s, 9H) ppm; 13C NMR (100 MHz, CDCl3) δ 155.3, 149.1, 146.5,
135.5 (4C), 133.6 (2C), 129.6 (2C), 127.6 (4C), 126.5, 124.8, 114.2,
97.1, 88.1, 83.5, 80.6, 62.8, 62.8 (2C), 44.7, 29.2, 27.3, 26.8 (3C), 26.1,
25.2, 19.1 ppm; HRMS (ESI+) calcd for C33H42N4O6Si
79Br 697.2052
[(M + H)+], found 697.2072, calcd for C33H42N4O6Si
81Br 699.2031
[(M + H)+], found 699.2032.
N1-[2′,3′-O-Isopropylidine-5′-O-(di-tert-butyl)phosphoryl-β-
D-ribofuranosyl]-N9-[4-(tert-butyldiphenylsilyl)oxybutyl)-8-
bromohypoxanthine (20). To a solution of 19 (350 mg, 0.502
mmol) in DCM (2.8 mL) was added 5-phenyl-1-H-tetrazole (147 mg,
1.003 mmol) and N,N-diisopropyldibutylphosphoramidite (238 μL,
0.753 mmol). After 2 h, the solution was cooled to 0 °C and Et3N
(419 μL, 3.012 mmol) and H2O2 (138 μL, 1.255 mmol) were added.
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The solution was allowed to warm to rt and stirred for a further 2 h,
after which DCM (20 mL) and H2O were added. The organic layer
was washed with NaHCO3 (sat. aq), then brine, dried (Na2SO4), and
evaporated to dryness. The residue was puriﬁed by column
chromatography on silica gel, eluting with PE/EtOAc (1:0 → 1:0 v/
v), where both solvents contained 0.5% v/v pyridine, to aﬀord the title
compound (356 mg, 80%) as a colorless glass. Rf = 0.43 (PE/EtOAc
1:3 v/v); 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H, H-2), 7.63−7.60
(m, 4H), 7.40−7.32 (m, 6H) (10 × Ar-H), 5.97 (d, 1H, J = 1.8, H-1′),
5.08 (dd, 1H, J = 6.4, 1.8, H-2′), 4.99 (dd, 1H, J = 6.4, 3.9, H-3′), 4.41
(dd, 1H, J = 9.6, 4.3, H-4′), 4.27−4.13 (m, 4H, both H-5′ and CH2),
3.67 (t, 2H, J = 6.0, CH2), 1.93−1.89 (m, 2H, CH2), 1.57 (s, 3H),
1.55−1.44 (m, 2H, CH2), 1.448 (s, 9H), 1.447 (s, 9H), 1.33 (s, 3H),
1.02 (s, 9H) ppm; 13C NMR (100 MHz, CDCl3) δ 153.0, 147.2, 144.1,
133.7 (4C), 131.9 (2C), 127.8 (2C), 125.8 (4C), 124.2, 122.7, 112.5,
92.5, 85.1 (d, J = 7.9), 83.2, 80.9 (d, 2C, J = 7.2), 79.7, 64.7 (d, J =
6.2), 61.1, 42.8, 28.0 (d, 3C, J = 2.8), 27.9 (d, 3C, J = 2.9), 27.5, 25.3,
25.0 (3C), 24.4, 23.5, 17.3 ppm; 31P NMR (162 MHz, 1H decoupled,
CDCl3) δ −10.2 ppm; HRMS (ESI+) calcd for C41H58N4O9PSi79BrNa
911 . 2786 [(M + H)+] , f ound 911 .2762 , c a l cd f o r
C41H58N4O9PSi
81BrNa 913.2766 [(M + H)+], found 913.2763.
N1-[2′,3′-O-Isopropylidine-5′-O-(di-tert-butyl)phosphoryl-β-
D-ribofuranosyl]-N9-(4-hydroxybutyl)-8-bromohypoxanthine
(21). Acetic acid (12 μL, 0.213 mmol) and TBAF·3H2O (64 mg, 0.203
mmol) were stirred in DMF (0.5 mL) for 30 min, after which the
solution was cooled to 0 °C and 20 (60 mg, 0.068 mmol) in DMF (0.5
mL) added. The resulting solution was allowed to warm to rt and
stirred for a further 4 h. The solution was diluted with ether, and
NaHCO3 (sat. aq) and NH3Cl (sat. aq) were added. The organic layer
was separated and the aqueous layer extracted with ether (×3). The
combined organic layers were dried (Na2SO4), evaporated to dryness
and the residue was puriﬁed by column chromatography on silica gel,
eluting with DCM/acetone (1:0 → 1:0 v/v) to aﬀord the title
compound (44 mg, 100%) as a colorless glass. Rf = 0.47 (DCM/
acetone 1:1 v/v); 1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H, H-2),
5.98 (d, 1H, J = 1.8, H-1′), 5.05 (dd, 1H, J = 6.4, 1.8, H-2′), 4.96 (dd,
1H, J = 6.4, 3.9, H-3′), 4.39 (app. dd, 1H, J = 9.0, 4.5, H-4′), 4.25−
4.11 (m, 4H, both H-5′ and CH2), 3.65 (t, 2H, J = 6.3, CH2), 2.34 (bs,
1H, OH), 1.89 (app. quintet, 2H, J = 7.2, CH2), 1.56 (app. quintet,
2H, J = 6.3, CH2), 1.55 (s, 3H), 1.44 (s, 9H), 1.43 (s, 9H), 1.31 (s,
3H) ppm; 13C NMR (100 MHz, CDCl3) δ 154.7, 149.0, 145.9, 125.9,
124.4, 114.2, 94.1, 86.8 (d, J = 7.9), 85.1, 82.71 (d, J = 7.3), 82.69 (d, J
= 7.2), 81.3, 66.4 (d, J = 6.3), 61.7, 44.5, 29.74 (d, 3C, J = 4.2), 29.72
(d, 3C, J = 4.3), 29.1, 27.1, 26.2, 25.2 ppm; 31P NMR (162 MHz, 1H
decoupled, CDCl3) δ −10.4 ppm; HRMS (ESI+) calcd for
C25H40N4O9P
79BrNa 673.1608 [(M + H)+], found 673.1584, calcd
for C25H40N4O9P
81BrNa 675.1588 [(M + H)+], found 675.1570.
N1-[2′,3′-O-Isopropylidine-5′-O-(di-tert-butyl)phosphoryl-β-
D-r ibofuranosyl] -N9-(4-[ (diphenylthio)phosphoryl ] -
hydroxybutyl)-8-bromohypoxanthine (22). Intermediate 21 (20
mg, 0.031 mmol) was coevaporated from pyridine (3 × 1 mL) and
taken up in pyridine (0.5 mL). This solution was added to PSS (35
mg, 0.092 mmol) which had also been coevaporated from pyridine (3
× 1 mL). 5-Phenyl-1-H-tetrazole (13 mg, 0.092 mmol) and TPS-Cl
(19 mg, 0.061 mmol) were added, and the solution was stirred at rt for
5 h. DCM and H2O were added. The organic layer was separated and
the aqueous layer washed with DCM (×2). The combined organic
layer was washed with brine, dried (Na2SO4), and evaporated to
dryness. The residue was puriﬁed by column chromatography on silica
gel, eluting with PE/EtOAc (1:0 → 1:0 v/v) to aﬀord the title
compound (28 mg, 100%) as a white foam. Rf = 0.73 (DCM/acetone
1:1 v/v); 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H, H-2), 7.52−7.49
(m, 4H), 7.36−7.30 (m, 6H) (10 × ArH), 5.97 (d, 1H, J = 1.8, H-1′),
5.07 (dd, 1H, J = 6.4, 1.8, H-2′), 4.98 (dd, 1H, J = 6.4, 3.9, H-3′), 4.40
(app. dd, 1H, J = 9.4, 5.2, H-4′), 4.25−4.17 (m, 4H, both H-5′ and
CH2), 4.11 (t, 2H, J = 7.0, CH2), 1.82 (app. quintet, 2H, J = 7.2, CH2),
1.66 (app. quintet, 2H, J = 6.3, CH2), 1.56 (s, 3H), 1.454 (s, 9H),
1.449 (s, 9H), 1.32 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ
154.7, 149.0, 146.0, 135.2 (d, 4C, J = 5.2), 129.4 (d, 2C, J = 3.2), 129.3
(d, 4C, J = 2.5), 126.3 (d, 2C, J = 6.7), 125.8, 124.5, 114.3, 94.3, 86.8
(d, J = 7.9), 85.0, 82.8 (d, 2C, J = 7.3), 81.4, 67.0 (d, J = 8.7), 66.5 (d, J
= 6.2), 43.9, 29.77 (d, 3C, J = 4.2), 29.74 (d, 3C, J = 4.2), 27.1, 27.0 (d,
J = 6.7), 25.6, 25.2 ppm; 31P NMR (162 MHz, 1H decoupled, CDCl3)
δ 49.0, −10.3 ppm; HRMS (ESI+) calcd for C37H49N4O10P2S279BrNa
937 .1441 [ (M + H)+] , f ound 937 . 1447 , c a l cd fo r
C37H49N4O10P2S2
81BrNa 939.1420 [(M + H)+], found 939.1440.
N1 - [5 ′ -O - Phospho ry l -β - D - r i bo fu ranosy l ] -N9 - (4 -
[ (diphenylthio)phosphoryl ]hydroxybutyl ) -8-bromo-
hypoxanthine (23). Intermediate 22 (40 mg, 0.044 mmol) was
stirred in 50% TFA (2 mL) at 0 °C for 4 h. All solvents were
evaporated, and the residue was coevaporated with MeOH (×4). The
residue was puriﬁed by column chromatography on silica gel, eluting
with EtOAc/MeOH/H2O (1:0:0 → 4:2:0 → 7:2:1 v/v/v) to aﬀord
the title compound (33 mg, 100%) as a colorless glass. Rf = 0.20
(EtOAc/MeOH/H2O 7:2:1 v/v/v);
1H NMR (500 MHz, MeOD) δ
8.59 (s, 1H, H-2), 7.43 (dd, 4H, J = 7.1, 0.7), 7.33−7.28 (m, 6H) (10
× ArH), 6.21 (d, 1H, J = 3.8, H-1′), 4.24 (d, 2H, J = 2.6, H-2′ and H-
3′), 4.16−4.07 (m, 7H, H-4′, both H-5′ and 2 × CH2), 1.70 (app
quintet, 2H, J = 7.1, CH2), 1.55 (app quintet, 2H, J = 5.7, CH2) ppm;
13C NMR (125 MHz, MeOD) δ 157.2, 150.6, 147.1, 136.6 (d, 4C, J =
5.3), 131.1 (d, 2C, J = 3.4), 130.7 (d, 4C, J = 2.5), 127.6, 127.0 (d, 2C,
J = 6.8), 124.5, 89.8, 85.6 (d, J = 8.6), 77.1, 71.4, 69.2 (d, J = 8.9), 65.3
(d, J = 4.8), 45.2, 28.3 (d, J = 7.0), 26.8 ppm; 31P NMR (202 MHz, 1H
decoupled, MeOD) δ 50.8, 0.8 ppm; HRMS (ESI−) calcd for
C26H28N4O10P2S2
79Br 760.9911 [(M − H)−], found 760.9878, calcd
for C26H28N4O10P2S2
81Br 762.9890 [(M − H)−], found 762.9915.
N1 - (5 ′ -O - Phospho ry l -β - D - r i bo fu ranosy l ) -N9 - (4 -
[ (diphenylthio)phosphoryl ]hydroxybutyl ) -8-bromo-
hypoxanthine (24). Intermediate 23 (20 mg, 0.026 mmol) was taken
up in dioxane/H2O (1 mL, 1:1 v/v). NaOH (100 μL, 1 M) was added
and the solution stirred for 30 min at rt before addition of HCl (100
μL, 1M). The solution was diluted with H2O and washed with hexane
(×3) before evaporation of all solvents to give a colorless glass which
was converted to the TEA salt as described below. 31P NMR (202
MHz, 1H decoupled, D2O) δ 15.6, 2.6 ppm; HRMS (ESI
−) calcd for
C20H24N4O11P2S
79Br 668.9826 [(M − H)−], found 668.9853, calcd for
C20H24N4O11P2S
81Br 670.9806 [(M − H)−], found 670.9863.
Conversion to TEA salt: The Na+ salt was passed through prewashed
Dowex H+ resin. Acidic fractions were neutralized with TEAB (2 mL,
1 M). All solvents were evaporated, and the residue was coevaporated
with H2O to remove excess buﬀer. The colorless glass obtained was
used directly for cyclization.
N1-Cyclic-8-bromohypoxanthine-N9-hydroxybutyl Diphos-
phate Ribose (8-Br-N9-butyl-cIDPR, 5). Intermediate 24 (0.026
mmol) was evaporated from pyridine (2 × 2 mL). The residue was
taken up in pyridine (10 mL) and placed in a syringe. This solution
was added over 15 h to a solution of iodine (70 mg, 0.30 mmol) and 3
Å molecular sieves (0.5 g) in pyridine (20 mL), in the dark. The
solution was ﬁltered through Celite, washed with H2O. After addition
of TEAB (2 mL) all solvents were evaporated, and the residue was
partitioned between H2O and CHCl3. The aqueous layer was washed
with CHCl3 and evaporated to dryness. The residue was puriﬁed by
semipreparative HPLC (1.1 cm × 25 cm C18 column), eluting with
acetonitrile/0.1 M TEAB (1:19 → 13:7 v/v) over 25 min. Fractions
were analyzed by analytical HPLC and appropriate fractions collected
and evaporated under vacuum to give the title compound (3.0 mg,
21% over two steps). UV (H2O, pH 7), λmax = 256 nm (ε = 19 900);
1H NMR (500 MHz, D2O) δ 8.81 (s, 1H, H-2), 6.08 (d, 1H, J = 1.8,
H-1′), 4.43 (dd, 1H, J = 4.7, 1.8, H-2′), 4.38 (dd, 1H, J = 6.9, 4.7, H-
3′), 4.35−4.19 (m, 4H), 4.17 (app septet, 1H, J = 5.1, CHaH), 4.11
(dd, 1H, J = 11.0, 3.9, H-5b′), 1.92−1.83 (m, 2H, CH2), 1.41−1.38 (m,
1H, CHaH), 1.13−1.07 (m, 1H, CHbH) ppm; 13C NMR (125 MHz,
D2O) δ 156.7, 150.1, 145.0, 127.7, 122.6, 91.1, 83.5 (d, J = 8.9), 75.2,
68.1, 65.2 (d, J = 6.0), 62.8 (d, J = 4.3), 42.9, 24.8 (d, J = 9.8), 23.7
ppm; 31P NMR (202 MHz, D2O,
1H-decoupled) δ −10.2 (d, J = 14.9
Hz), −11.4 (d, J = 14.9 Hz) ppm; HRMS (ESI−) calcd for
C14H18N4O11P2
79Br 558.9636 [(M − H)−], found 558.9627; calcd
for C14H18N4O11P2
81Br 560.9616 [(M − H)−], found 560.9612.
N1-Cyclic Hypoxanthine-N9-hydroxybutyl Diphosphate Ri-
bose (N9-Butyl-cIDPR, 4). Analog 5 (7.0 mg, 0.0125 mmol) was
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taken up in Milli-Q (3 mL), and NaHCO3 (225 mg, 2.77 mmol) was
added. When all material had dissolved, EtOH (1.5 mL) and then Pd/
C (6 mg) were added and the solution was placed under an
atmosphere of H2. After 5 h stirring, the solution was ﬁltered and all
solvents evaporated. The residue was puriﬁed by semipreparative
HPLC (1.1 cm × 25 cm C18 column), eluting with MeCN/0.1 M
TEAB (1:19 → 13:7 v/v) over 25 min. Fractions were analyzed by
analytical HPLC and appropriate fractions collected and evaporated
under vacuum to give the title compound (4.6 mg, 76%). UV (H2O,
pH 7), λmax = 252 nm (ε = 11 400);
1H NMR (500 MHz, D2O) δ 8.79
(s, 1H, H-2), 8.03 (s, 1H, H-8), 6.10 (s, 1H, H-1′), 4.49 (d, 1H, J =
3.0, H-2′), 4.40 (app. t, 1H, J = 3.0, H-3′), 4.33−4.24 (m, 4H), 4.11
(dd, 1H, J = 11.8, 4.4, H-5b′), 4.05 (app septet, 1H, J = 5.2, CHaH),
3.81 (app septet, 1H, J = 5.2, CHbH), 1.96−1.84 (m, 2H, CH2), 1.41−
1.35 (m, 1H, CHaH), 1.11−1.05 (m, 1H, CHbH) ppm; 13C NMR
(125 MHz, D2O) δ 158.0, 148.9, 144.7, 142.3, 122.2, 91.1, 83.6 (d, J =
8.9), 75.2, 68.3, 65.1 (d, J = 5.9), 63.0 (d, J = 4.5), 42.3, 25.4, 25.0 (d, J
= 9.5) ppm; 31P NMR (202 MHz, D2O,
1H-decoupled) δ −10.3 (d, J
= 14.1), −11.2 (d, J = 14.2) ppm; HRMS (ESI−) calcd for
C14H19N4O11P2 481.0531 [(M − H)−], found 481.0522.
N1-Cyclic-8-azidohypoxanthine-N9-hydroxybutyl Diphos-
phate Ribose (8-N3-N9-butyl-cIDPR, 6). Analog 5 (4.5 mg, 8.0
μmol) was converted to the free acid by addition of Milli-Q (5 mL)
and stirring with Dowex 50WX8 (H+ form) for 30 min. The resin was
removed by ﬁltration, washed with Milli-Q and the combined ﬁltrate
evaporated. The residue was evaporated from dry DMF (4 × 2 mL),
taken up in DMF (1 mL), and stirred under argon. TMSN3 (50 μL,
0.43 mmol) was added and the resulting solution stirred at 70 °C in
the dark for 16 h, after which ∼65% conversion of the starting material
to product was observed by HPLC (λ = 255 nm → λ = 277 nm). All
solvent was evaporated and the resulting residue coevaporated with
Milli-Q (2 × 5 mL). The residue was then taken up in Milli-Q (5 mL),
ﬁltered through cotton wool, and puriﬁed by semipreparative HPLC
(1.1 cm × 25 cm C18 column), eluting with acetonitrile/Milli-Q (1:19
→ 13:7 v/v) over 25 min. Fractions were analyzed by analytical HPLC
and appropriate fractions were collected and evaporated under vacuum
to give the title compound (2.4 mg, 57%). UV (H2O, pH 7), λmax =
252 nm (ε = 12 700); 1H NMR (500 MHz, D2O) δ 8.75 (s, 1H, H-2),
6.08 (d, 1H, J = 1.9, H-1′), 4.46 (dd, 1H, J = 4.8, 1.9, H-2′), 4.39 (dd,
1H, J = 6.5, 4.8, H-3′), 4.33−4.30 (m, 2H, H-4′, CHH), 4.12−4.05 (m,
3H, H-5′a, 2 × CHH), 4.00 (dt, 1H, J = 14.5, 5.2, H-5′b), 3.81 (app
septet, 1H, J = 5.0, CHH), 1.81−1.76 (m, 2H, CH2), 1.40−1.36 (m,
1H, CHH), 1.14−1.09 (m, 1H, CHH) ppm; 13C NMR (125 MHz,
D2O) 156.6, 149.0, 146.4, 144.2, 120.3, 91.2, 83.6 (d, J = 8.9), 75.2,
68.2, 65.1 (d, J = 6.5), 62.9 (d, J = 4.4), 40.7, 24.9 (d, J = 9.1), 23.5
ppm; 31P NMR (202 MHz, D2O) −10.4 (d, J = 14.1), −11.4 (d, J =
14.1) ppm; HRMS (ESI−) found m/z [M − H]− 522.0549;
C14H18N7O11P2 requires 522.0545.
N1-Cyclic-8-aminohypoxanthine-N9-hydroxybutyl Diphos-
phate Ribose (8-NH2-N9-butyl-cIDPR, 7). Analog 5 (4.5 mg, 8.0
μmol) was converted to the free acid by addition of Milli-Q (5 mL)
and stirring with Dowex 50WX8 (H+ form) for 30 min. The resin was
removed by ﬁltration, washed with Milli-Q and the combined ﬁltrate
evaporated. The residue was evaporated from dry DMF (4 × 2 mL),
taken up in DMF (1 mL), and stirred under argon. TMSN3 (50 μL,
0.43 mmol) was added and the resulting solution stirred at 70 °C in
the dark for 16 h, after which ∼70% conversion of the starting material
to product was observed by HPLC (λ = 255 nm → λ = 277 nm). All
solvent was evaporated, and the resulting residue was taken up in
TEAB (5 mL, 0.05 M). Dithiothreitol (12 mg, 0.08 mmol) was added
and the solution stirred under an atmosphere of argon for 16 h. The
crude material was directly puriﬁed by semipreparative HPLC (1.1 cm
× 25 cm C18 column), eluting with acetonitrile/0.1 M TEAB (1:19 →
13:7 v/v) over 25 min. Fractions were analyzed by analytical HPLC
and appropriate fractions collected and evaporated under vacuum to
give the title compound (2.7 mg, 68% over two steps). UV (H2O, pH
7), λmax = 252 nm (ε = 14 700);
1H NMR (400 MHz, D2O) δ 8.80 (s,
1H, H-2), 6.19 (d, 1H, J = 2.1, H-1′), 4.56 (dd, 1H, J = 4.7, 2.1, H-2′),
4.50 (dd, 1H, J = 6.4, 4.7, H-3′), 4.43−4.41 (m, 2H, H-4′, CHH),
4.27−4.20 (m, 3H, H-5′a, 2 × CHH), 4.11 (ddd, 1H, J = 15.0, 5.3, 4.9,
H-5′b), 3.95 (app septet, 1H, J = 5.3, CHH), 2.00−1.85 (m, 2H,
CH2), 1.53−1.50 (m, 1H, CHH), 1.31−1.28 (m, 1H, CHH) ppm; 13C
NMR (125 MHz, D2O) 155.3, 152.2, 148.3, 143.2, 116.7, 91.1, 83.5
(d, J = 8.9), 75.2, 68.1, 65.1 (d, J = 5.6), 62.9 (d, J = 3.1), 39.7, 24.8 (d,
J = 9.6), 22.5 ppm; 31P NMR (202 MHz, D2O) −10.39 (br), −11.44
(br); HRMS (ESI−) found m/z [M − H]− 496.0637; C14H20N5O11P2
requires 496.0640.
Enzyme Assay for cADPR Hydrolysis. The inhibition of cADPR
hydrolysis by various concentrations of analog (0−1 mM) was
determined by incubating 1 μM cADPR with 1 μg/mL CD38 catalytic
domain for 10 min at 20−24 °C in 25 mM sodium acetate, pH 4.5.
The reaction was stopped by the addition of 150 mM HCl. The
precipitated protein was ﬁltered, and the pH was neutralized with Tris
base. After the mixture was diluted 20-fold, the concentration of the
unhydrolyzed cADPR present in the diluted reaction mixture was
assayed by the ﬂuorimetric cycling assay as described previously.52
Modeling of the Butyl Compounds. The 2PGJ crystal structure
of human CD38 with cIDPR was passed through the Protein
Preparation Wizard in the Schrödinger software (http://www.
schrodinger.com/). Four N9-butyl compounds, where the cIDPR
“southern” ribose is replaced by a four carbon linker, were built using
the Schrödinger software. The four compounds diﬀered in the
substituent at the 8-position: hydrogen, bromine, azido, or an amino
group. The compounds were docked into the 2PGJ structure using
GOLD.58 The binding site was deﬁned as a sphere of 5 Å radius
centered on the centroid of the cIDPR ligand: the centroid of the
docked ligand has to lie within this sphere. Each ligand was docked 25
times. The best ranked pose of each of the ligands was merged with
the protein structure, and the resulting complex was passed through a
minimization procedure using the Schrödinger software.
Crystallization, Diﬀraction Data Collection, and Structure
Reﬁnement. The human CD38 catalytic domain was expressed and
puriﬁed as described previously.45,54 The protein was diluted to 10
mg/mL for crystallization trials. Crystals of wild type CD38 were
obtained by the hanging droplet vapor diﬀusion method with the
reservoir buﬀer in 0.1 M sodium acetate, pH 4.0, 15% PEG 10K, 0.2 M
ammonium acetate, and 3% isopropanol. They were harvested and
soaked in 0.1 M sodium acetate, pH 4.0, 15% PEG 10K, 16% ethylene
glycerol, and 5 mM compound 7 for 1 h at 295 K and then ﬂash-frozen
in liquid nitrogen. The diﬀraction data were collected at 100 K on
beamline BL17U at the Shanghai Synchrotron Radiation Facility and
processed with HKL2000.59 Molecular replacement was performed
using the program Phaser60 from the CCP4 suite,61 and the wild-type
human CD38 (PDB code 1YH3) was used as the search model. The
model was reﬁned with Refmac62 and then cycled with manual
building in Coot.63 Hydrolyzed compound 7 was built into positive
diﬀerence electron-density maps of the CD38 model after a few
restrained reﬁnement runs with the stereochemical restraints
generated from the program PRODRG.64 TLS reﬁnement65 was
incorporated into the later stages of the reﬁnement process. Solvents
were added automatically in Coot and then manually inspected and
modiﬁed. The ﬁnal model was analyzed with MolProbity,66 showing
that 98% residues were in the Ramachandran favored region with only
one residue (D202 in chain B) in the Ramachandran outlier region.
Data collection and model reﬁnement statistics are summarized in
Supporting Information Table 1. The coordinates and structure factors
are deposited in the Protein Data Bank with the code 4TMF.
HPLC Studies. The solution containing the CD38 catalytic domain
was adjusted to the desired concentration using Tris-HCl buﬀer (20
mM, pH 8), and 50 μL therefrom was added to the inhibitor (0.05
μmol) in an Eppendorf tube at room temperature. At a given time
point, a sample of 5 μL was removed and diluted with 95 μL of Milli-Q
water. Then 10 μL of this sample was injected directly into the
analytical HPLC system (see section General in Experimental
Section), eluting at 1 mL/min with an isocratic ion-pair buﬀer:
0.17% (m/v) cetrimide and 45% (v/v) phosphate buﬀer (pH 6.4) in
MeOH.
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